Trupanion (NASDAQ:TRUP – Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Trupanion to post earnings of $0.16 per share and revenue of $402.53 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
Trupanion (NASDAQ:TRUP – Get Free Report) last issued its earnings results on Wednesday, August 5th. The financial services provider reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. Trupanion had a net margin of 1.53% and a return on equity of 5.96%. The firm had revenue of $392.93 million for the quarter, compared to analysts’ expectations of $389.72 million. During the same quarter last year, the company posted $0.22 earnings per share. Trupanion’s revenue was up 11.1% on a year-over-year basis. On average, analysts expect Trupanion to post $0.63 EPS for the current fiscal year and $0.70 EPS for the next fiscal year.
Trupanion Stock Performance
Shares of TRUP stock opened at $29.52 on Thursday. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.24. The business has a 50 day moving average of $26.92 and a two-hundred day moving average of $26.75. Trupanion has a 52 week low of $21.16 and a 52 week high of $46.98. The company has a market cap of $1.30 billion, a P/E ratio of 55.70, a PEG ratio of 1.75 and a beta of 1.44.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on TRUP shares. Atlantic Securities set a $42.00 price target on Trupanion in a research report on Wednesday, July 15th. Cantor Fitzgerald cut their price target on Trupanion from $34.00 to $30.00 and set a “neutral” rating on the stock in a report on Wednesday, October 7th. Piper Sandler lowered Trupanion from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $45.00 to $32.00 in a research report on Wednesday, August 26th. Zacks Research lowered Trupanion from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Finally, Weiss Ratings upgraded Trupanion from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, September 29th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Trupanion presently has an average rating of “Hold” and a consensus price target of $38.40.
Read Our Latest Stock Analysis on Trupanion
Insider Activity at Trupanion
In other Trupanion news, CFO Fawwad Qureshi sold 6,111 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $30.01, for a total transaction of $183,391.11. Following the completion of the transaction, the chief financial officer directly owned 4,230 shares of the company’s stock, valued at $126,942.30. The trade was a 59.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Margaret Tooth sold 1,000 shares of the company’s stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $25.84, for a total transaction of $25,840.00. Following the completion of the transaction, the chief executive officer owned 184,952 shares of the company’s stock, valued at approximately $4,779,159.68. This trade represents a 0.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,615 shares of company stock worth $395,193 in the last ninety days. 5.58% of the stock is owned by insiders.
About Trupanion
Trupanion, Inc is a pet insurance company that provides medical insurance coverage for cats and dogs. Its products are designed to help pet owners manage the cost of veterinary care, including coverage for eligible illnesses, injuries and other qualifying medical conditions, subject to the terms of each policy.
The company offers subscription-based pet insurance through the Trupanion brand, with coverage generally intended for ongoing veterinary expenses rather than routine or preventive care.
See Also
- Five stocks we like better than Trupanion
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.
